Primary Biliary News Today

Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver

Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.

The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.

Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The

Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 millionTopline interim...

Results from the phase 3 trial showed seladelpar elicited biochemical response, normalized alkaline phosphatase, and reduced pruritus at a greater rate than placebo.

Phase 1 trial initiated to assess safety/tolerability and absolute bioavailability of TH104 with topline data expected in 2Q24Planning well underway for Phase 2 of TH104 in primary biliary cholangitis (PBC) patients suffering from moderate-to-severe chronic pruritusCompany outlines near-clinical pipeline of novel an...

This article focuses on cholangiocyte biology and incidence of cholangiopathies.1

March 7, 1960-Jan. 15 2024 NEW ULM—Bradley B. Zollner, age 63, of New Ulm died Monday, January 15, 2024, at the University of Minnesota Medical Center in Mi

The post-hoc analysis of the phase 3 ENHANCE study provides the first published evidence of a correlation between decreases in IL-31, bile acids, and pruritus symptoms in PBC following treatment with an investigational agent.